{
  "id": 198560,
  "name": "BIOTECHNOLOGY INNOVATION ORGANIZATION",
  "slug": "biotechnology-innovation-organization",
  "state": "DC",
  "description": "Biotech trade association.",
  "totalSpending": 1470000,
  "filings": 25,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 150000
    },
    {
      "year": 2019,
      "income": 240000
    },
    {
      "year": 2020,
      "income": 120000
    },
    {
      "year": 2021,
      "income": 240000
    },
    {
      "year": 2022,
      "income": 180000
    },
    {
      "year": 2023,
      "income": 240000
    },
    {
      "year": 2024,
      "income": 300000
    }
  ],
  "firms": [
    "TODD STRATEGY GROUP"
  ],
  "lobbyists": [
    "DANIEL TODD",
    "PAUL EDATTEL",
    "ERIC BERGREN",
    "KATHERINE COTTON",
    "TED LEHMAN",
    "JEFF LUCAS",
    "TAYLOR SEXTON",
    "NICHOLAS UEHLECKE",
    "KIMBERLY LINTHICUM"
  ],
  "issues": [
    "MMM",
    "PHA",
    "HCR",
    null
  ],
  "sampleDescriptions": [
    "Medicare and Medicaid Innovation Center.\nMedicare reimbursement for biosimilars.\nPrescription drug payment reform.",
    "Drug Pricing and Access.",
    "Medicare and Medicaid Innovation Center.\nMedicare reimbursement for biosimilars.\nPrescription drug payment reform.\nPresident's American Patients First Blueprint.",
    "COVID-19 Response.",
    "Medicare and Medicaid Innovation Center.\nPrescription drug payment reform.",
    "Drug pricing and access.",
    "COVID-19 response.",
    "Prescription drug payment reform.",
    "Prescription drug payment reform.\nH.R.5376 - Build Back Better Act.\nH.R.3684 - Infrastructure Investment and Jobs Act.",
    "Drug pricing and access.\nH.R.5376 - Build Back Better Act.\nH.R.3684 - Infrastructure Investment and Jobs Act.",
    "Prescription drug payment reform. H.R.5376 - Build Back Better Act.",
    "Drug pricing and access. H.R.5376 - Build Back Better Act. FDA User Fees.",
    "Prescription drug payment reform. H.R.5376 - Inflation Reduction Act of 2022. 21st Century Cures Act 2.0. 340B Drug Discount Program.",
    "Drug pricing and access. H.R.5376 - Inflation Reduction Act of 2022. FDA User Fees. Biosimilars. COVID-19 Response. H.R.4128/S.2209 - VALID Act.",
    "Biosimilars. PBM Reform",
    "Drug pricing and access. Implementation of Inflation Reduction Act of 2022. Pandemic and All-Hazards Preparedness Act (PAHPA). Priority Pediatric Review Voucher (PPRV).",
    "Biosimilars. PBM Reform."
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024
  ],
  "growthRate": 100,
  "trajectory": "growing",
  "yearsActive": 7,
  "avgAnnualSpending": 210000,
  "peakYear": 2024,
  "lobbyistCount": 9,
  "firmCount": 1,
  "issueCount": 3,
  "industry": "technology"
}